Stocksigma LogoStocksigma Logo

Concord Biotech Reports Solid Q2FY27 Results, Approves 1:1 Bonus Issue

Concord Biotech delivered strong consolidated performance for the period ended 30th Sep'26, with Q2FY27 revenue rising 25.1% YoY to ₹309.1 Cr, driven by

Concord Biotech Reports Solid Q2FY27 Results, Approves 1:1 Bonus Issue

Concord Biotech Ltd · Investor Presentation · 28 Oct 2026, 1:51 am

Concord Biotech Reports Solid Q2FY27 Results, Approves 1:1 Bonus Issue Concord Biotech delivered strong consolidated performance for the period ended 30th Sep'26, with Q2FY27 revenue rising 25.1% YoY to ₹309.1 Cr, driven by broad-based demand and a 30% expansion in API sales to ₹250.2 Cr. EBITDA grew 18.0% YoY to ₹104.4 Cr (33.8% margin), while PAT climbed 10.3% YoY to ₹69.6 Cr. For H1FY27, revenue reached ₹566.6 Cr (+25.6% YoY) and PAT rose to ₹127.3 Cr (+19.0% YoY). The company approved a 1:1 bonus share issue, launched dermatology division Inspira, and secured ANDA approvals for Tofacitinib and MMF OS.

Original exchange filing (PDF)

More announcements from Concord Biotech Ltd

All Concord Biotech Ltd announcements